{
  "success": true,
  "pagesUsed": [
    8,
    9,
    10,
    11,
    12,
    13,
    22,
    23,
    24,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that QW LY3298176 10 mg and/or 15 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Efficacy Objective 1",
        "text": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Key Secondary Efficacy Objective 2",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Key Secondary Efficacy Objective 3",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Key Secondary Efficacy Objective 4",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for the proportion of patients with HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Additional Secondary Efficacy Objective",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Safety Objective",
        "text": "To compare the safety of LY3298176 5 mg, 10 mg, and 15 mg LY3298176 to insulin glargine at 52 weeks and at the end of the safety follow-up period",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10",
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Pharmacokinetics Objective",
        "text": "To characterize the pharmacokinetics (PK) of LY3298176 5 mg, 10 mg, and 15 mg and evaluate the relationships between LY3298176 exposure and safety, tolerability, and efficacy measures",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Glycemic Objective",
        "text": "To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_20"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Comparison Objective",
        "text": "To compare LY3298176 5 mg, 10 mg, and 15 mg to insulin glargine with respect to lipids, BMI, waist circumference, biomarkers, and PROs",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24",
          "ep_25"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Body Weight Endpoint",
        "text": "Mean change in body weight",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Superiority HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "HbA1c Target <7.0% Endpoint",
        "text": "HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Fasting Serum Glucose Endpoint",
        "text": "The mean change in fasting serum glucose (central laboratory) from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "HbA1c Target ≤6.5% and <5.7% Endpoint",
        "text": "The proportion of patients achieving an HbA1c target value of ≤6.5% (48 mmol/mol) and <5.7% (39 mmol/mol)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "SMBG Profile Endpoint",
        "text": "Mean change in 7-point self-monitored blood glucose profiles from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Weight Loss Percentage Endpoint",
        "text": "Proportion of patients who achieved weight loss of ≥5%, >10%, and >15% from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "TEAE Endpoint",
        "text": "Treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Discontinuation due to AE Endpoint",
        "text": "Early discontinuations of study drug due to adverse events (AEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "CV Events Endpoint",
        "text": "Adjudicated deaths and nonfatal major CV events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Pancreatic AE Endpoint",
        "text": "Adjudicated pancreatic AEs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Thyroid/Calcitonin Endpoint",
        "text": "Medullary thyroid carcinoma (MTC), C-cell hyperplasia, and serum calcitonin",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Immunogenicity Endpoint",
        "text": "Incidence of treatment-emergent LY3298176 anti-drug antibodies and systemic hypersensitivity reactions",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Vital Signs Endpoint",
        "text": "Mean change in systolic and diastolic blood pressure and heart rate from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Hypoglycemia Endpoint",
        "text": "Occurrence of hypoglycemic events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_18",
        "name": "Rescue Therapy Endpoint",
        "text": "Time to initiation of rescue therapy for severe, persistent hyperglycemia",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_19",
        "name": "PK/PD Parameters Endpoint",
        "text": "Population PK and PD parameters",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_20",
        "name": "Exploratory HbA1c Endpoint",
        "text": "HbA1c",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Lipids Endpoint",
        "text": "Change in lipids (total cholesterol, high-density lipoproteins, low-density lipoproteins, very low-density lipoproteins, and triglycerides) from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_22",
        "name": "BMI Endpoint",
        "text": "Changes from baseline in mean body mass index (BMI)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_23",
        "name": "Waist Circumference Endpoint",
        "text": "Change in waist circumference",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_24",
        "name": "Exploratory Biomarkers Endpoint",
        "text": "Biomarkers",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_25",
        "name": "PROs Endpoint",
        "text": "Patient-Reported Outcomes (European Quality of Life – dimensions [EQ-5D-5L], Ability to Perform Physical Activities of Daily Living [APPADL], Impact of Weight on Self-Perception [IW-SP], status (s) and change (c) versions of Diabetes Treatment Satisfaction Questionnaire (DTSQ)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Treatment-Regimen Estimand (Primary)",
        "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (ANCOVA).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study drug",
            "text": "Participants discontinue the study drug before the 52-week visit",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue therapy",
            "text": "Introduction of rescue therapy for persistent severe hyperglycemia",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
        "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means (ANCOVA)"
      },
      {
        "id": "est_2",
        "name": "Efficacy Estimand",
        "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (MMRM).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Discontinuation of study drug",
            "text": "Premature treatment discontinuation",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Rescue therapy",
            "text": "Initiation of any rescue therapy",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
        "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means (MMRM)"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Body Weight Estimand",
        "populationSummary": "Modified intention-to-treat (mITT) population Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation or rescue",
            "text": "Events affecting the measurement of weight at 52 weeks",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population",
        "variableOfInterest": "Mean change in body weight from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 7,
      "exploratoryObjectives": 2,
      "totalEndpoints": 25,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that QW LY3298176 10 mg and/or 15 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Efficacy Objective 1",
        "text": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Key Secondary Efficacy Objective 2",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Key Secondary Efficacy Objective 3",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Key Secondary Efficacy Objective 4",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for the proportion of patients with HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Additional Secondary Efficacy Objective",
        "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine at 52 weeks",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Safety Objective",
        "text": "To compare the safety of LY3298176 5 mg, 10 mg, and 15 mg LY3298176 to insulin glargine at 52 weeks and at the end of the safety follow-up period",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10",
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Pharmacokinetics Objective",
        "text": "To characterize the pharmacokinetics (PK) of LY3298176 5 mg, 10 mg, and 15 mg and evaluate the relationships between LY3298176 exposure and safety, tolerability, and efficacy measures",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Glycemic Objective",
        "text": "To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_20"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Comparison Objective",
        "text": "To compare LY3298176 5 mg, 10 mg, and 15 mg to insulin glargine with respect to lipids, BMI, waist circumference, biomarkers, and PROs",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24",
          "ep_25"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Body Weight Endpoint",
        "text": "Mean change in body weight",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Superiority HbA1c Endpoint",
        "text": "Mean change in HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "HbA1c Target <7.0% Endpoint",
        "text": "HbA1c",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Fasting Serum Glucose Endpoint",
        "text": "The mean change in fasting serum glucose (central laboratory) from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "HbA1c Target ≤6.5% and <5.7% Endpoint",
        "text": "The proportion of patients achieving an HbA1c target value of ≤6.5% (48 mmol/mol) and <5.7% (39 mmol/mol)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "SMBG Profile Endpoint",
        "text": "Mean change in 7-point self-monitored blood glucose profiles from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Weight Loss Percentage Endpoint",
        "text": "Proportion of patients who achieved weight loss of ≥5%, >10%, and >15% from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "TEAE Endpoint",
        "text": "Treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Discontinuation due to AE Endpoint",
        "text": "Early discontinuations of study drug due to adverse events (AEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "CV Events Endpoint",
        "text": "Adjudicated deaths and nonfatal major CV events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Pancreatic AE Endpoint",
        "text": "Adjudicated pancreatic AEs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Thyroid/Calcitonin Endpoint",
        "text": "Medullary thyroid carcinoma (MTC), C-cell hyperplasia, and serum calcitonin",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Immunogenicity Endpoint",
        "text": "Incidence of treatment-emergent LY3298176 anti-drug antibodies and systemic hypersensitivity reactions",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Vital Signs Endpoint",
        "text": "Mean change in systolic and diastolic blood pressure and heart rate from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Hypoglycemia Endpoint",
        "text": "Occurrence of hypoglycemic events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_18",
        "name": "Rescue Therapy Endpoint",
        "text": "Time to initiation of rescue therapy for severe, persistent hyperglycemia",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_19",
        "name": "PK/PD Parameters Endpoint",
        "text": "Population PK and PD parameters",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_20",
        "name": "Exploratory HbA1c Endpoint",
        "text": "HbA1c",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Lipids Endpoint",
        "text": "Change in lipids (total cholesterol, high-density lipoproteins, low-density lipoproteins, very low-density lipoproteins, and triglycerides) from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_22",
        "name": "BMI Endpoint",
        "text": "Changes from baseline in mean body mass index (BMI)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_23",
        "name": "Waist Circumference Endpoint",
        "text": "Change in waist circumference",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_24",
        "name": "Exploratory Biomarkers Endpoint",
        "text": "Biomarkers",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_25",
        "name": "PROs Endpoint",
        "text": "Patient-Reported Outcomes (European Quality of Life – dimensions [EQ-5D-5L], Ability to Perform Physical Activities of Daily Living [APPADL], Impact of Weight on Self-Perception [IW-SP], status (s) and change (c) versions of Diabetes Treatment Satisfaction Questionnaire (DTSQ)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Treatment-Regimen Estimand (Primary)",
        "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (ANCOVA).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study drug",
            "text": "Participants discontinue the study drug before the 52-week visit",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue therapy",
            "text": "Introduction of rescue therapy for persistent severe hyperglycemia",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
        "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means (ANCOVA)"
      },
      {
        "id": "est_2",
        "name": "Efficacy Estimand",
        "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (MMRM).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Discontinuation of study drug",
            "text": "Premature treatment discontinuation",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Rescue therapy",
            "text": "Initiation of any rescue therapy",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
        "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means (MMRM)"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Body Weight Estimand",
        "populationSummary": "Modified intention-to-treat (mITT) population Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation or rescue",
            "text": "Events affecting the measurement of weight at 52 weeks",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
        "analysisPopulation": "Modified intention-to-treat (mITT) population",
        "variableOfInterest": "Mean change in body weight from baseline to 52 weeks",
        "summaryMeasure": "Difference in least squares means"
      }
    ]
  }
}